Incorporated in 2006, Anthem Biosciences Limited operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) with end-to-end capabilities spanning drug discovery, development, and manufacturing. The company caters to a global customer base, including emerging biotech firms and large pharmaceutical companies. Its product portfolio includes fermentation-based active pharmaceutical ingredients (APIs) such as enzymes, probiotics, peptides, biosimilars, and vitamin analogues. As of September 30, 2024, Anthem was involved in 196 projects, including discovery, early and late-phase, and commercial manufacturing projects. The company supported ten commercial molecules from discovery through production.
Anthem Biosciences’ CRDMO platform comprises five primary modalities—RNAi, ADC, peptides, lipids, and oligonucleotides—along with four manufacturing capabilities: custom synthesis, flow chemistry, fermentation, and biotransformation. As of March and September 2024, the company served over 550 and 425 customers respectively, across more than 44 countries, including the U.S., Japan, and Europe. The company’s workforce includes 600 professionals from diverse scientific disciplines, and it holds one patent in India, seven internationally, with 24 global patent applications pending.